Lanifibranor, the only pan-PPAR agonist, was assessed in non-cirrhotic biopsy-confirmed highly active NASH (stages 0–3) patients in a phase 2b trial (NATIVE study) were 1200 mg showed better results than 800 mg dose or placebo in histological resolution of NASH (49% and 39%, respectively, vs. 22%), histological improvement of fibrosis (48% and 34%, respectively, vs. 29%), or both (35% and 25%, respectively, vs. 9%) were observed [43]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.